FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis| Regeneron (NASDAQ: REGN) | Delayed: 609.94 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $609.94 | 52 Week High | $592.36 | |||
| Open | $609.94 | 52 Week Low | $325.35 | |||
| Day High | $609.94 | P/E | 160.09 | |||
| Day Low | $609.94 | EPS | $3.81 | |||
| Volume | 217 | |||||
